Table 2.

The SWI/SNF complex submits targets in tumor therapy

Cancer	Submits	Antineoplastic drugs	Outcome	Ref
Lung adenocarcinoma with mEGFR mutations	ARID1A, ARID1B, BCR, BM10	Icotinib	Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations	[212]
Lung cancer, head/neck cancer	BRG1, BRM	Cisplatin	Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity	[245]
Ovarian cancer	SMARCA2/4	Cisplatin	Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer	[246]
			Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance	[244]
	ARID1A	GSH, GCLC	Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers	[248]
Pancreatic cancer	ARID1A	Cisplatin, Oxaliplatin, Gemcitabine	ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2	[249]
Breast Cancer	SMARCA4	Cisplatin	SMARCA4 Depletion Induces Cisplatin Resistance by Activating YAP1-Mediated Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer	[251]